Nursing Pharmacology Chapter 33-34: Cancer Chemotherapy
Topoisomerase Inhibitors Practice Questions
Click on the correct answer.
Camptothecins-based antineoplastic drugs have an enzyme topoisomerase I as their target
- True
- False
Camptothecin analog(s) approved for clinical use:
- Irinotecan
- Topotecan
- Both
- Neither
Inhibitors of topoisomerase II:
- Campothecins
- Anthracyclines
- Both
- Neither
Irinotecan:
- Irinotecan is a prodrug
- Irinotecan is approved as monotherapy in treating metastatic colorectal cancer
-
-
Irinotecan may be used as a single agent and second-line treatment of advancing colorectal cancer following 5-fluorouracil-based treatment.
- True
- False
Combination chemotherapy involving irinotecan in combination with oxaliplatin and 5-fluorouracil (5-FU):
- First-line treatment pancreatic cancer
- First-line treatment of melanoma
- Both
- Neither
Irinotecan is considered first-line treatment in combination with cisplatin or carboplatin for extensive-stage small-cell lung cancer.
- True
- False
Primary adverse effect associated with irinotecan (Camptosar):
- Liver cirrhosis
- Myelosuppression
- Both
- Neither
Topotecan (Hycamtin) has been approved for management of ovarian cancer following initial treatment failure.
- True
- False
Topotecan (Hycamtin) may be used (FDA approved) for treating small cell lung cancer if initial therapy has failed.
- True
- False
|
If
you wish to return to the Table of Contents in ENGLISH, press
the RETURN button above. |
|
Otherwise, if the text is NOT displayed in English and
you are ready to leave this page,
Press here
to return to the Table of Contents
 |